| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Pharming Group N.V.$14.46
+0.15 (+1.05%)
C 53Pipeline Score Fair Value Pharma · Clinical
Market Cap
915.92 M
EPS
0.18
P/E Ratio
73.09 $
Value Trade
56.40 K
-2.48 %
Week
-26.4 %
1 Month
-23.26 %
3 Month
-23.03 %
6 Month
4.83 %
5 Year
-21.35 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
4.63 K
52 Week Range
9.54 - 21.34
% held by Insiders
-
% held by Institutions
1.33 %
Enterprise Value
861.23 M
Total Shares
70.63 M
Short %
-
Float Shares
-
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Pharming Group N.V.
341Total events
10Upcoming
88Tier-1 (high impact)
2004 – 2028Coverage
Upcoming catalysts 10
Event history 331
Q3 2026
◆NDA SubmissionJoenja®ApprovedRegulatory Filing
Separate sNDA for lower weight pediatric patients planned for second half 2026
APDS in pediatric patients weighing less than 27 kgsource ↗
Jun 4, 2026
◆Oral PresentationPresentation
Pharming CEO participates in Fireside Chat at Jefferies Global Healthcare Conference
Jun 4, 2026
▲FDA Filing AcceptedJoenja®ApprovedRegulatory Filing
FDA accepts sNDA resubmission for Joenja for children aged 4-11 with APDS
APDS in children aged 4 to 11 yearssource ↗
May 8, 2026
◆Poster PresentationLeniolisibApprovedPresentation
Phase 2 Clinical Study of Leniolisib in Primary Immunodeficiencies with Enhanced PI3K Pathway Signaling: Study Design & Subject Baseline Characteristics
Primary Immunodeficiencies with Enhanced PI3K Pathway Signalingsource ↗
May 8, 2026
◆Poster PresentationPresentation
Caregivers of Children with APDS Balance Complex Medical Care, Family, and Work Responsibilities
APDSsource ↗
May 7, 2026
May 7, 2026
◆Poster PresentationLeniolisibApprovedPresentation
Clinical Experience with Use of Leniolisib to Treat Immune Dysregulation in Patients with CVID and CVID-Like Disorders
CVID and CVID-like disorderssource ↗
May 7, 2026
◆Poster PresentationPresentation
Pediatric and Adolescent APDS: Demographic and Clinical Findings from the APDS-CHOIR Registry
APDSsource ↗
May 7, 2026
●NDA SubmissionJoenja®ApprovedRegulatory Filing
Resubmitted pediatric sNDA for 40 mg and 50 mg doses
APDSsource ↗
May 7, 2026
▲Enrollment CompleteLeniolisibApprovedTrial
Enrollment completed in two Phase II trials for leniolisib in PIDs
primary immunodeficiencies with immune dysregulationsource ↗
May 7, 2026
●Oral PresentationLeniolisibApprovedPresentation
Presentation at CIS Annual Meeting on leniolisib compassionate use in CVID
CVID and CVID-like disorderssource ↗
Drug Pipeline Intelligence
C53
Pipeline Score $1.3B
Pipeline ValueFair Value
Valuation Signal8
Drugs Scored1.5x
rNPV / MCap Top 80%
Micro Cap (rank 182 of 906)
Percentile RankPharming Group N.V. carries a moderate pipeline score (53/100), with $4.4B risk-adjusted pipeline value, led by Recombinant Human C1 Inhibitor in Genetic Disorders (Phase 2), across $63B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recombinant human C1 inhibitor Monoclonal antibody | Hereditary Angioedema | Phase 3 | NCT02247739 | 57% | $1.3B | COMPLETED | 184 | - | - | Sep 1, 2016 | - | Dec 8, 2017 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
leniolisib PriorityOrphan | activated PI3K delta syndrome (APDS) | Phase 3 | 2026-03-24 | significantly reducing lymphadenopathy; significantly increasing the percentage of naïve B cells out of total B cells Read More | Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older Read More | |
leniolisib PriorityOrphan | activated PI3K delta syndrome (APDS) | Phase 3 | 2026-03-24 | significantly reducing lymphadenopathy; significantly increasing the percentage of naïve B cells out of total B cells Read More | Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older Read More | |
leniolisib PriorityOrphan | activated PI3K delta syndrome (APDS) | Phase 3 | 2026-03-24 | significantly reducing lymphadenopathy; significantly increasing the percentage of naïve B cells out of total B cells Read More | Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PHAR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PHAR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
PHARPharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
Pharming Group announced the FDA's acceptance of its resubmitted supplemental New Drug Application for Joenja (leniolisib) to treat children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). If approved, Joenja will be the first treatment for this rare immunodeficiency in the U.S. The resubmission includes additional data requested by the FDA and has a target action date of October 24, 2026.
Read more →PHAR▼ -6.3%on this newsshared move
Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New York
Pharming Group announced its participation in the 2026 Jefferies Global Healthcare Conference in New York, scheduled for June 3-4, 2026. CEO Fabrice Chouraqui will take part in a Fireside Chat Q&A session on June 4 at 11:05am EDT. The event will be accessible via a live webcast and replay on Pharming's website.
Read more →PHARPharming Group announces results of 2026 Annual General Meeting of Shareholders
Pharming Group held its Annual General Meeting of Shareholders on May 28, 2026, where all proposed agenda items were approved. Key decisions included the appointment of KPMG as the independent auditor for 2026-2028 and amendments to the remuneration policy for Non-Executive Directors. Shareholders also renewed authorizations for share issuance and repurchase.
Read more →PHAR▼ -26.8%on this news
Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders
Pharming Group N.V. announced its participation in the 2026 Annual Meeting of the Clinical Immunology Society, where it will present interim outcomes from a long-term study of leniolisib in pediatric patients with activated PI3Kδ syndrome (APDS). The presentations will also cover clinical data from leniolisib's use in treating immune dysregulation in patients with Common Variable Immunodeficiency (CVID) and related disorders. Two phase II trials are currently evaluating leniolisib's safety and tolerability in these patient populations.
Read more →PHAR▼ -26.8%on this newsshared move
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026
Pharming Group reported its Q1 2026 financial results, revealing total revenues of $72.4 million, an 8% decrease from the previous year. Notably, Joenja® saw a 34% revenue increase, driven by strong uptake in the U.S. and international markets. The company reaffirmed its revenue guidance for 2026 and made significant regulatory progress, including approvals in Japan and a positive opinion from the CHMP in Europe.
Read more →PHARPharming Group to report first quarter 2026 financial results and provide business update on May 7
Pharming Group N.V. has announced that it will report its preliminary financial results for the first quarter of 2026 and provide a business update on May 7, 2026. Management will host a conference call and webcast for analysts and investors at 13:30 CEST/07:30 am EDT on the same day. Interested participants can register in advance for both the conference call and the webcast. Following the event, a replay will be available on the Pharming website.
Read more →PHARPharming Group announces the 2026 Annual General Meeting of Shareholders
Pharming Group N.V. has scheduled its 2026 Annual General Meeting of Shareholders for May 28, 2026. The agenda includes appointing KPMG N.V. as the external auditor and proposals to amend the remuneration policy for Non-Executive Directors. Additionally, the Board will seek renewal of share issuance and repurchase authorizations. The meeting will be held at the Corpus Congress Centre and will be webcast live.
Read more →PHARPharming Group N.V. Investigated by the Portnoy Law Firm
Pharming Group N.V. is currently facing an investigation by the Portnoy Law Firm due to potential securities fraud. This follows a dramatic decline in the company's stock price after the FDA's issuance of a Complete Response Letter concerning the supplemental New Drug Application for Joenja® (leniolisib). The FDA highlighted significant issues regarding pediatric dosing and manufacturing practices, prompting investor concern and legal scrutiny. As the firm prepares to possibly file a class action on behalf of investors, it emphasizes the seriousness of the company's regulatory challenges.
Read more →PHARPharming Group to participate in April investor conferences
Pharming Group N.V. has announced its participation in two investor conferences in April 2026. The CEO and CMO will present at the Needham Virtual Healthcare Conference on April 13, followed by attendance at the Van Lanschot Kempen Life Sciences Conference in Amsterdam on April 15. This engagement aims to strengthen investor relations and showcase Pharming's innovative portfolio.
Read more →PHARPharming Group announces the filing of its 2025 Annual Report and Form 20-F
Pharming Group N.V. has announced the filing of its Annual Report for the year ending December 31, 2025, which is now available online. Additionally, the company has filed its Annual Report on Form 20-F with the U.S. SEC. Pharming is committed to developing innovative treatments for patients with rare diseases.
Read more →PHARPharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older
Pharming Group has received a positive opinion from the CHMP recommending marketing authorization for Joenja (leniolisib) to treat activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 and older. This decision is based on Phase II/III clinical trial results showing significant improvements in immune dysregulation. A final decision from the European Commission is anticipated by Q2 2026.
Read more →PHARPharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older
Pharming Group has received approval from Japan's Ministry of Health for Joenja® (leniolisib) as the first treatment for activated PI3K delta syndrome (APDS) in patients aged 4 and older. This approval is based on positive results from Phase III studies, including a pediatric trial. Joenja is now the only targeted treatment option for APDS in Japan, marking a significant milestone for patients and families affected by this rare disease.
Read more →PHARPharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
Pharming Group reported a strong financial performance for the full year 2025, with total revenues rising by 27% to $376.1 million, driven by growth in RUCONEST® and Joenja® sales. The company achieved a significant operating profit of $25.8 million, marking a turnaround from the previous year's loss. Looking ahead, Pharming anticipates continued revenue growth in 2026, with guidance set between $405 million and $425 million, alongside key clinical milestones.
Read more →PHARPharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12
Pharming Group N.V. has announced it will release its preliminary financial results for Q4 and the full year 2025 on March 12, 2026. The company will also provide a business update during a conference call and webcast scheduled for the same day. This event underscores Pharming's commitment to transparency and investor engagement.
Read more →PHAR▲ +5.7%on this news
Pharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Pharming Group N.V. will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026. CEO Fabrice Chouraqui and CMO Anurag Relan will present on February 25. A live webcast of the presentation will be available on Pharming's website, and investors can schedule one-on-one meetings with management.
Read more →PHARPharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day
Pharming Group N.V. has announced its 2026 financial guidance, projecting revenues between $405 million and $425 million. The company will highlight its rare disease pipeline at an upcoming Investor Day, focusing on two key programs: leniolisib for primary immunodeficiencies and napazimone for mitochondrial diseases. Both programs are supported by ongoing clinical trials and aim to address significant unmet medical needs.
Read more →PHAR▼ -17.1%on this newsshared move
Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS
Pharming Group received a Complete Response Letter from the FDA regarding its supplemental New Drug Application for Joenja (leniolisib) in children aged 4 to 11 with activated phosphoinositide 3-kinase delta syndrome (APDS). The FDA raised concerns about potential underexposure in lower weight patients and requested additional pharmacokinetic data. Despite this setback, Pharming aims to address the FDA's issues and plans to request a Type A meeting to discuss resubmission.
Read more →PHARPharming Group reports preliminary 2025 revenues and announces Investor Day
Pharming Group N.V. announced its preliminary revenues for 2025, estimating approximately $376 million, which exceeds earlier guidance and represents a 27% growth from 2024. The company attributes this success to rising demand for its products, particularly RUCONEST® and Joenja®, alongside ongoing geographic expansion. An Investor Day is scheduled for February 3, 2026, to discuss the company's clinical pipeline, including updates on leniolisib and KL1333. Pharming's commitment to financial discipline is evident as it anticipates operating expenses to remain within earlier communicated ranges.
Read more →PHARPharming Group to participate in Oppenheimer Movers in Rare Disease Summit
Pharming Group N.V. announced its participation in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025, in New York City. The event will feature a fireside chat by Dr. Anurag Relan, focusing on the hereditary angioedema market. This invitation-only summit aims to connect innovative companies and investors in the rare disease sector.
Read more →PHAR▲ +11.5%on this news· ran to +34% by day 5
Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow
Pharming Group N.V. reported strong financial results for Q3 2025, with revenues reaching $97.3 million, a 30% increase year-over-year. The company highlighted significant growth in its RUCONEST® and Joenja® products, driven by increased patient enrollments. Pharming also announced a strategic withdrawal from non-U.S. markets for RUCONEST® and raised its full-year revenue guidance. Organizational changes include the appointment of a new Chief Commercial Officer.
Read more →PHARPharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London
Pharming Group N.V. will participate in the Jefferies Global Healthcare Conference in London from November 17-20, 2025. CEO Fabrice Chouraqui is scheduled for a Fireside Chat Q&A session on November 19. The event will be accessible via a live webcast on Pharming's website, enhancing investor engagement.
Read more →PHAR▲ +13.1%on this newsshared move
Pharming Group to report third quarter 2025 financial results and provide business update on November 6
Pharming Group N.V. will report its third quarter 2025 financial results and provide a business update on November 6, 2025. A conference call and webcast for analysts and investors will take place on the same day. Participants need to register in advance to access the call. Pharming is dedicated to developing innovative treatments for rare diseases.
Read more →PHARPharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio
Pharming Group N.V. announced that 12 abstracts have been accepted for presentation at the ACAAI 2025 Annual Scientific Meeting. The presentations will include positive clinical data for RUCONEST® in treating hereditary angioedema and new findings on Joenja®'s effectiveness in pediatric patients with activated phosphoinositide 3-kinase delta syndrome. The meeting will take place in Orlando, Florida from November 6-10, 2025.
Read more →PHARPharming Group provides update on previously announced G&A expense reduction plan
Pharming Group N.V. has announced an organizational restructuring aimed at accelerating growth and reducing general and administrative expenses by 15%, equating to $10 million annually. This plan includes a 20% reduction in headcount at its Netherlands headquarters and will incur one-time costs of about $7 million. The company has consulted with its Dutch Works Council regarding these changes.
Read more →PHAR▲ +6.1%on this newsshared move
Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years
Pharming Group announced that the FDA has accepted its supplemental New Drug Application for leniolisib, aimed at treating children aged 4 to 11 with activated phosphoinositide 3-kinase delta syndrome (APDS). The application has been granted Priority Review, with a target action date of January 31, 2026. This follows positive Phase III study results demonstrating improvements in key clinical markers for the condition.
Read more →PHAR▼ -9.1%on this news
Pharming Group promoted to the Euronext AMX® index
Pharming Group N.V. has been promoted from the Euronext AScX to the AMX index, effective September 22, 2025. This move highlights the company's strong growth and aims to enhance its visibility to investors. CEO Fabrice Chouraqui emphasized the importance of this inclusion for Pharming's future prospects in the rare disease sector.
Read more →PHARPharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference
Pharming Group N.V. will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025. CEO Fabrice Chouraqui is scheduled to present on September 8 at 1:30 PM EDT. The event will be accessible via a live webcast, and investors can arrange one-on-one meetings with the management team.
Read more →PHAR▼ -5.9%on this newsshared move
Pharming Group appoints Kenneth Lynard as Chief Financial Officer
Pharming Group N.V. has appointed Kenneth Lynard as Chief Financial Officer, effective October 1, 2025. Lynard, a seasoned finance executive with over 20 years of experience in the life sciences sector, is expected to enhance Pharming's financial leadership amid strong growth. His previous roles include CFO positions at notable companies, including Gilead Sciences.
Read more →PHAR▲ +11.8%on this news
Pharming Group to participate in August investor conference
Pharming Group N.V. has announced its participation in an investor conference scheduled for August. The company's management will be available for one-to-one meetings, highlighting their commitment to investor engagement. Pharming is focused on developing innovative medicines for patients with rare and life-threatening diseases.
Read more →PHAR▲ +10.1%on this news· ran to +24% by day 3shared move
Pharming Group reports second quarter and first half 2025 financial results and provides business update
Pharming Group announced its financial results for the second quarter and first half of 2025, reporting a 26% increase in total revenues to US$93.2 million. Key revenue drivers included strong sales growth from RUCONEST® and Joenja®, with respective revenues of US$80.4 million and US$12.8 million. The company has raised its revenue guidance for the year, bolstered by recent developments including a new drug application for Joenja® in Japan. Additionally, a study highlights the potential for a significant increase in the prevalence of APDS, presenting new opportunities for patient growth.
Read more →PHARPharming Group to report second quarter and first half 2025 financial results and provide business update on July 31
Pharming Group N.V. has announced that it will report its preliminary financial results for the second quarter and first half of 2025 on July 31, 2025. In addition to the financial updates, the company will provide a business update during a conference call and webcast scheduled for the same day. The event aims to engage analysts and investors and will include an opportunity for dial-in attendees to ask questions. Pharming is dedicated to developing innovative medicines for patients with rare and serious illnesses.
Read more →PHAR▲ +8.6%on this news
Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis
Pharming Group will host a webcast on new research findings published in the journal Cell, focusing on the functional classification of genetic variants associated with activated phosphoinositide 3-kinase delta syndrome (APDS). The study, led by a team from Columbia University, reveals over 100 new variants linked to PI3Kδ pathway hyperactivity. These developments are expected to aid clinical genetic testing labs in reclassifying variants of uncertain significance, potentially accelerating APDS diagnoses for many patients. The webcast is scheduled for June 30, 2025, featuring renowned immunologist Dr. Joshua Milner among others.
Read more →PHARPharming Group reports on results of the 2025 Annual General Meeting of Shareholders
Pharming Group N.V. held its Annual General Meeting of Shareholders on June 11, 2025, where all proposed measures were approved. Dr. Elaine Sullivan was appointed to the Board of Directors, enhancing the leadership expertise of the company. Additionally, the reappointment of Deloitte Accountants as external auditors was confirmed, alongside renewed authorizations for share issuance and repurchase. Notably, two long-serving Board members chose not to stand for re-election, marking a transition in the Board's composition.
Read more →PHAR▼ -7.2%on this news
Pharming Group to participate in June investor conferences
Pharming Group N.V. has announced its participation in two investor conferences in June 2025, namely the Jefferies Global Healthcare Conference in New York and the Portzamparc Mid & Small Caps Conference in Paris. CEO Fabrice Chouraqui will host a Fireside Chat Q&A at the Jefferies conference. These events present opportunities for Pharming to engage with investors and provide updates on their portfolio of innovative medicines.
Read more →PHAR▲ +11.2%on this news
Pharming Group reports first quarter 2025 financial results and provides business update
Pharming Group N.V. reported a robust first quarter for 2025, with total revenues climbing to US$79.1 million, an impressive 42% year-over-year increase. The company's flagship product, RUCONEST®, reported a 49% growth in revenue, driven by strong demand in the U.S. market. Joenja® (leniolisib) also experienced positive momentum with an 18% increase in volume. However, the departure of CFO Jeroen Wakkerman raises concerns about future financial leadership as the company prepares for a filing for pediatric FDA approval.
Read more →PHARPharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director
Pharming Group N.V. has announced its 2025 Annual General Meeting of Shareholders scheduled for June 11, featuring the nomination of Dr. Elaine Sullivan as a new Non-Executive Director. Alongside this, current directors Deborah Jorn and Steven Baert will not seek reappointment. The agenda also includes reappointments of existing directors and a proposal to renew share issuance and repurchase authorizations. The AGM will take place at the Corpus Congress Centre in Oegstgeest, Netherlands, and will be webcast live.
Read more →PHARPharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)
Pharming Group N.V. announced its upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society, showcasing Phase III clinical data for leniolisib in pediatric patients with activated PI3Kδ syndrome. Presenters will include experts from notable institutions, and several topics on immune dysregulation and immunodeficiencies will be discussed. While leniolisib has been approved for older patients, its efficacy in younger children remains unverified by regulatory bodies, and there are cautions regarding the translation of preclinical data to clinical outcomes.
Read more →PHARPharming Group to report first quarter 2025 financial results on May 8
Pharming Group N.V. has announced that it will report its preliminary first quarter 2025 financial results on May 8, 2025. A conference call will be held for analysts and investors where only dial-in attendees will be allowed to ask questions. The company, focused on developing treatments for rare and life-threatening diseases, seeks to enhance transparency and communication with stakeholders through this upcoming presentation.
Read more →PHARPharming receives positive recommendation from NICE for Joenja ▼(leniolisib) as a treatment for APDS
Pharming Group N.V. has received a positive recommendation from the National Institute for Health and Care Excellence (NICE) for its drug Joenja (leniolisib) as a treatment option for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in patients aged 12 and older. This marks a significant milestone as Joenja is the first targeted therapy to be reimbursed by the NHS, facilitating patient access in England and Wales. The recommendation is based on favorable results from the Phase III clinical trials that demonstrated marked clinical improvements in patients suffering from this rare immunodeficiency. Immediate funding through the NHS has been established, ensuring that patients can access this treatment without delay.
Read more →PHAR▼ -8.1%on this news
Pharming Group announces the filing of its 2024 Annual Report and Form 20-F
Pharming Group N.V. has announced the filing of its Annual Report for the fiscal year ending December 31, 2024. The report is available on the company's website under the Investors/Financial documents section. Additionally, Pharming filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission, also accessible through the SEC website. This filing reflects the company's continued commitment to transparency and communication with its investors.
Read more →PHARPharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation
Pharming Group N.V. has announced the dosing of the first patient in a Phase II clinical trial for leniolisib, aimed at treating common variable immunodeficiency (CVID) with immune dysregulation. This trial will assess the drug's safety, tolerability, pharmacokinetics, and efficacy in a population lacking effective therapies. Conducted across multiple sites in the US, UK, and EU, the trial focuses on individuals aged 12 and older diagnosed with CVID accompanied by immune dysregulation. The company expresses confidence in leniolisib's potential to meet a large, unmet medical need for these patients.
Read more →PHAR▲ +12.9%on this newsshared move
Pharming Group reports fourth quarter and full year 2024 financial results and provides business update
Pharming Group reported a strong financial performance for the full year 2024, with total revenues rising by 21% to US$297.2 million, driven largely by a notable increase in revenues from its products, RUCONEST® and Joenja® (leniolisib). The fourth quarter saw a revenue growth of 14% compared to the previous year, with significant increases in operating profit. Pharming has also strengthened its pipeline through the acquisition of Abliva AB, which enhances its late-stage clinical offerings. Looking ahead to 2025, the company anticipates continued growth driven by regulatory reviews and strong ongoing clinical trials.
Read more →PHARPharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders
Pharming Group N.V. held its Extraordinary General Meeting of Shareholders on March 4, 2025, where shareholders approved all agenda proposals. Fabrice Chouraqui has been appointed as the new Executive Director and CEO for a four-year term, succeeding Sijmen de Vries, who will transition to a strategic advisor role until the end of 2025. The approval of Mr. Chouraqui's remuneration package was also granted, indicating confidence in the leadership change. The company aims to strengthen its presence in the rare disease market under the new CEO.
Read more →PHARPharming Group to participate in March investor conference
Pharming Group N.V. announced participation in the 37th Annual Roth Conference, taking place in Dana Point, California, from March 16-18, 2025. Company executives Anurag Relan and Michael Levitan will engage in a fireside chat session on March 17. This highlights Pharming's commitment to investor relations and provides an opportunity for direct communication with stakeholders. The company offers therapies for patients with rare and life-threatening diseases.
Read more →PHAR▼ -6.6%on this newsshared move
Pharming Group to report fourth quarter and full year 2024 financial results on March 13
Pharming Group N.V. has announced that it will report its preliminary fourth quarter and full year 2024 financial results on March 13, 2025. Following the financial disclosure, the company will host a conference call for analysts and investors. The event provides a platform for discussion, encouraging registered dial-in attendees to ask questions. Pharming continues to emphasize its commitment to developing therapies for rare and life-threatening diseases.
Read more →PHAR▲ +5%on this newsshared move
Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent
Pharming Technologies B.V. has significantly increased its stake in Abliva AB to 92.70%, following a successful cash offer to shareholders. The offer was accepted by approximately 87.71% of shareholders by February 7, 2025, with additional shares tendered during an extended acceptance period. Pharming now intends to initiate a compulsory acquisition of the remaining shares under Swedish law and plans to delist Abliva shares from Nasdaq Stockholm.
Read more →PHARPharming Group to participate in February investor conference
Pharming Group N.V. announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference, scheduled for February 11-12, 2025. CEO Sijmen de Vries and CMO Anurag Relan will present on February 12 at 08:40 ET/14:40 CET. A live webcast and replay will be available on Pharming's website. This conference serves as a platform for Pharming to showcase its developments in biopharmaceuticals and connect with investors.
Read more →PHARPharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period
Pharming Technologies B.V. has declared its cash offer for Abliva AB unconditional after receiving acceptance for approximately 87.7% of the shares. The acceptance period has been extended until February 20, 2025, to allow remaining shareholders to participate. Pharming will complete the acquisition and expects settlement for the accepted shares to begin around February 14, 2025. Additionally, Pharming plans to initiate a compulsory acquisition procedure if it acquires more than 90% of the shares.
Read more →PHARPharming Group to convene Extraordinary General Meeting of Shareholders
Pharming Group N.V. has announced the scheduling of an Extraordinary General Meeting (EGM) on March 4, 2025, to appoint Mr. Fabrice Chouraqui as the new CEO, succeeding Mr. Sijmen de Vries. The meeting agenda also includes approval of Mr. Chouraqui's remuneration package. Shareholders are encouraged to attend in person or via live webcast, with all related documents available on the company's website. This leadership change is positioned as part of Pharming's ongoing commitment to its stakeholders and strategic development.
Read more →PHARPharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer
Pharming Group N.V. has nominated Fabrice Chouraqui as the new Executive Director and CEO, succeeding Sijmen de Vries. Chouraqui, a seasoned executive with extensive experience in the pharmaceutical and biotech sectors, will lead the company for a term of four years. De Vries, who has been with Pharming for 16 years, will transition to a strategic advisory role to ensure a smooth handover. The Board expressed confidence in Chouraqui's ability to drive Pharming's growth in the rare disease sector.
Read more →PHARPharming announces public cash offer to the shareholders of Abliva AB
Pharming Group N.V. has announced a public cash offer to acquire all outstanding shares of Abliva AB for approximately $66.1 million. This transaction aims to bolster Pharming's late-stage pipeline by adding Abliva's lead product, KL1333, which is currently undergoing pivotal clinical trials for mitochondrial diseases. The offer is supported by Abliva's Board of Directors, and Pharming plans to finance the acquisition with existing cash, expecting regulatory approvals before the end of the acceptance period. KL1333's promising interim trial results and wide potential patient base bolster its commercial prospects.
Read more →PHAR▲ +6.1%on this newsshared move
Pharming announces positive topline data in pediatric clinical trial of leniolisib
Pharming Group N.V. has announced positive topline data from its Phase III clinical trial of leniolisib, an investigational treatment for children aged 4 to 11 with activated phosphoinositide 3-kinase delta syndrome (APDS). The study demonstrated improved lymphoproliferation and immunophenotype in all 21 participants after a 12-week treatment period. Pharming plans to use this data for regulatory filings aimed at pediatric approvals, scheduled to start in 2025. These findings not only affirm expectations from prior studies in older patients but also indicate an important step in addressing a significant unmet medical need in young APDS patients.
Read more →PHARPharming Group to participate in November investor conference
Pharming Group N.V. will participate in the Jefferies London Healthcare Conference from November 19-21, 2024. CEO Sijmen de Vries is scheduled to present on November 20. The event will include a live webcast and a replay available on Pharming's website. This participation highlights Pharming's commitment to engaging with investors and showcasing its portfolio of products and therapies.
Read more →PHAR▼ -7.4%on this news
Pharming Group reports third quarter 2024 financial results and provides business update
Pharming Group N.V. reported a 12% increase in total revenues to US$74.8 million for Q3 2024, with significant contributions from RUCONEST® and Joenja®. Particularly, Joenja® saw a remarkable 72% rise in revenue. Pharming maintains its revenue guidance for 2024, projecting between US$280 million and US$295 million. However, the company announced the upcoming departure of CEO Sijmen de Vries, who will not seek reappointment after a lengthy tenure.
Read more →PHARPharming Group to report third quarter 2024 financial results on October 24
Pharming Group N.V. announced it will report preliminary third quarter 2024 financial results on October 24, 2024. A conference call for analysts and investors will be held that same day at 13:30 CEST. Participants must register in advance for both the conference call and the live webcast. The results will provide insight into the company's financial health and ongoing efforts in biopharmaceuticals.
Read more →PHARPharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation
Pharming Group N.V. has begun a Phase II clinical trial for leniolisib aimed at treating primary immunodeficiencies (PIDs) characterized by immune dysregulation. The study will enroll approximately 12 patients with conditions including ALPS-FAS, CTLA4 haploinsufficiency, and NFKB1 haploinsufficiency. This trial seeks to evaluate the safety, pharmacokinetics, and clinical efficacy of leniolisib, with preliminary findings expected to guide a future Phase III program. The trial is led by experts at the National Institutes of Health (NIH).
Read more →PHARPharming announces marketing authorization in the U.K. for Joenja (leniolisib)
Pharming Group N.V. has received marketing authorization from the U.K. Medicines and Healthcare products Regulatory Agency for Joenja (leniolisib) to treat activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome in patients aged 12 and older. This approval is significant as it is the first targeted therapy for APDS in the U.K. and follows the earlier FDA approval in the U.S. Pharming aims to improve healthcare access and outcomes for patients dealing with this rare disease. The drug is currently under evaluation for NHS reimbursement, expanding accessibility for patients in the U.K.
Read more →PHARPharming Group to participate in September investor conferences
Pharming Group N.V. will participate in two major investor conferences in September 2024. CEO Sijmen de Vries is scheduled to engage in a fireside chat at the Wells Fargo Healthcare Conference and present at the H.C. Wainwright 26th Annual Global Investment Conference. Both events aim to provide insights into Pharming's developments and connect the management team with investors. Live webcasts and replays of the presentations will be available on Pharming's website.
Read more →PHAR▼ -8.4%on this news
Pharming Group reports second quarter and first half 2024 financial results and provides business update
Pharming Group N.V. reported strong financial results for the second quarter and first half of 2024, with total revenues rising by 35% to US$74.1 million, largely driven by growth in RUCONEST® and Joenja®. The company remains on track to achieve its revenue guidance for the year, despite a decline in cash and marketable securities primarily due to convertible bond refinancing. Pharming is also making progress with patient enrollment for Joenja® and is actively working on additional clinical trials to expand the treatment's market opportunity.
Read more →PHARPharming Group to report second quarter and first half 2024 financial results on August 1
Pharming Group N.V. will report its preliminary financial results for the second quarter and first half of 2024 on August 1, 2024. The company will host a presentation for analysts and investors on the same day at 13:30 CEST. Participants can register to join the conference call or watch a live webcast, indicating Pharming's commitment to transparency and investor engagement.
Read more →PHARPharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union
Pharming Group N.V. provided an update regarding the review of its Marketing Authorisation Application (MAA) for leniolisib, intended for treating activated phosphoinositide 3-kinase delta syndrome (APDS). The Committee for Medicinal Products for Human Use (CHMP) acknowledged the positive safety and efficacy of leniolisib, but requested additional data related to manufacturing controls. Pharming received an extension until January 2026 to fulfill these requirements. Despite the delay, Pharming remains committed to meeting CHMP guidelines and continuing its clinical development efforts.
Read more →PHARPharming Group reports on results of the 2024 Annual General Meeting of Shareholders
Pharming Group N.V. successfully held its Annual General Meeting of Shareholders on May 21, 2024, where all proposed measures were approved. Notable outcomes include the reappointment of Barbara Yanni and Mark Pykett as Non-Executive Directors for four years. The shareholders also approved updates to the Remuneration Policy and authorized the Board of Directors to issue and repurchase shares. The meeting reaffirmed strong support from shareholders for the company's strategic direction.
Read more →PHARPharming Group to participate in May investor conference
Pharming Group N.V. has announced its participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference on May 20, 2024. The company's VP of Investor Relations and Corporate Communications, Michael Levitan, will be presenting at the event. This engagement offers potential opportunities for investors to have direct discussions with Pharming's management team. The conference will take place at NASDAQ in New York.
Read more →PHARPharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025
Pharming Group N.V. announced the early redemption of its remaining €125 million worth of convertible bonds due in 2025, utilizing its clean-up call option. As of April 26, 2024, only €1.9 million of these bonds remain outstanding following a prior repurchase of €123.1 million. The redemption will take place on June 18, 2024, at 100% of the principal amount, inclusive of accrued interest since January 21, 2024. Bondholders can exercise conversion rights until June 7, 2024, with a conversion price set at €2.0028 per share.
Read more →PHARPharming Group reports first quarter 2024 financial results and provides business update
Pharming Group N.V. reported significant financial growth for the first quarter of 2024, with revenues totaling US$55.6 million, a 31% increase compared to the same quarter in 2023. The revenue boost was primarily attributed to the successful U.S. launch of Joenja® and continued sales growth of RUCONEST®. The company maintains its positive outlook, expecting total revenues between US$280 million and US$295 million for the year. Additionally, Pharming has made progress in expanding the market for Joenja® through regulatory approvals and patient identification initiatives.
Read more →PHARPharming Group to report first quarter 2024 financial results on May 8
Pharming Group N.V. has announced that it will report its preliminary first quarter 2024 financial results on May 8, 2024. The report will cover the period ended March 31 and will be followed by a presentation for analysts and investors. Registration links for both the conference call and live webcast are provided in the announcement, indicating the company's commitment to transparency and investor engagement.
Read more →PHARPharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD ) 2024 Rare Impact Awards
Pharming Group N.V. has been honored as an Industry Innovator by the National Organization for Rare Disorders (NORD) at the upcoming Rare Impact Awards. This recognition is attributed to the commercialization of Joenja® (leniolisib), the first FDA-approved treatment for activated phosphoinositide 3-kinase delta syndrome (APDS). Joenja® aims to improve the lives of patients suffering from this rare condition. The accolade will be received at the Rare Impact Awards on June 8, 2024, celebrating Pharming's commitment to the rare disease community.
Read more →PHAR▲ +7.2%on this newsshared move
Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025
Pharming Group N.V. has announced the successful repurchase of €123.1 million of its 3.00% senior unsecured convertible bonds due 2025, equating to 98.5% of the total outstanding amount. The final settlement date for this repurchase is anticipated on April 26, 2024. The move supports Pharming's financial strategy, potentially allowing for early redemption of the remaining bonds if certain conditions are met. This action reflects the company's ongoing efforts in managing its debt and improving its financial position.
Read more →PHAR▼ -8.3%on this newsshared move
Pharming Group announces the placement of €100 million convertible bonds due 2029
Pharming Group N.V. has successfully placed €100 million in senior unsecured convertible bonds due 2029, fully subscribed through an accelerated book-building process. The funds will be utilized to repurchase existing convertible bonds due 2025, thus strengthening the company's financial position. The new bonds will carry a 4.50% annual coupon and are expected to start trading on the Frankfurt Stock Exchange following issuance. The company aims to enhance its flexibility for ongoing business strategies in the coming years.
Read more →PHAR▼ -8.3%on this newsshared move
Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025
Pharming Group N.V. has launched an offering of approximately €100 million in convertible bonds due 2029, aimed at strengthening its financial position. Concurrently, the company is inviting holders of its €125 million 2025 convertible bonds to tender their bonds for cash. The new bonds, set to be issued on April 25, 2024, will feature a coupon rate of 4.50% per annum. The proceeds from this offering will be used to repurchase the outstanding 2025 bonds, enhancing the company's flexibility for future business strategies.
Read more →PHARPharming announces completion of enrollment in pediatric clinical trial of leniolisib
Pharming Group N.V. has announced the completion of patient enrollment in its Phase III clinical trial evaluating leniolisib for children aged 4 to 11 with activated phosphoinositide 3-kinase delta syndrome (APDS). This multinational study is pivotal as it is the first clinical trial targeting younger pediatric patients with this rare immunodeficiency. Pharming plans to use the collected data for regulatory submissions aimed at pediatric approval of leniolisib globally starting in 2025. The safety and efficacy outcomes will be measured alongside health-related quality of life assessments to understand the treatment's impact.
Read more →PHARPharming Group announces the 2024 Annual General Meeting of Shareholders
Pharming Group N.V. has announced its 2024 Annual General Meeting (AGM) scheduled for May 21, 2024. The meeting will address the reappointment of Directors and update the Remuneration Policy, alongside authorizations for equity-related corporate actions. The AGM will be held at the Corpus Congress Centre in the Netherlands and streamed live for stakeholders. This meeting serves as an essential platform for decision-making in the company’s governance.
Read more →PHARPharming Group announces the filing of its 2023 Annual Report and Form 20-F
Pharming Group N.V. has filed its 2023 Annual Report and Form 20-F with the U.S. SEC. The report, which covers the company's financial performance for the year ended December 31, 2023, is available on their website. This filing emphasizes Pharming's commitment to transparency and its ongoing dedication to developing therapies for patients with rare diseases.
Read more →PHARPharming Group reports fourth quarter and full year 2023 financial results
Pharming Group N.V. reported a strong financial performance for 2023, with total revenues increasing by 19% to $245.3 million. The company achieved record revenues for its product RUCONEST®, totaling $73.3 million in Q4. Furthermore, the launch of Joenja® (leniolisib) has been promising, generating $18.2 million in its first year, with 81 patients on therapy. Pharming aims to continue expanding its market presence and product offerings in 2024, with a revenue guidance of $280 million to $295 million.
Read more →PHARPharming Group to report fourth quarter and full year 2023 financial results on March 14
Pharming Group N.V. has announced that it will report its preliminary fourth quarter and full year 2023 financial results on March 14, 2024. The company plans to host a presentation for analysts and investors, facilitating an interactive session through a conference call. This event reflects Pharming's ongoing commitment to transparency and engagement with stakeholders in the biopharmaceutical industry.
Read more →PHAR▼ -7.2%on this news
Pharming Group to participate in February investor conferences
Pharming Group N.V. announced its participation in two investor conferences in February 2024. CEO Sijmen de Vries will present at the Oppenheimer 34th Annual Healthcare Life Sciences Virtual Conference on February 13, followed by participation in the UBS European Healthcare Conference in London on February 28. The events provide an opportunity for investors to engage with the company's management and learn about Pharming's innovative biopharmaceutical portfolio.
Read more →PHARPharming Group announces updated full year 2023 guidance and Joenja U.S. launch update
Pharming Group N.V. has announced updated guidance for full year 2023, predicting a revenue increase of 19% to about US$245 million, driven by significant growth in RUCONEST® and Joenja® therapies. The company expects RUCONEST® revenues to grow by 10% and Joenja® revenues to reach around US$18 million. Additionally, there has been an increase in new patient enrollments contributing to the positive financial outlook, alongside the successful launch of Joenja® in the U.S. market. Pharming aims to expand its product offerings and market presence, anticipating further developments in rare disease therapies in the coming years.
Read more →PHARPharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)
Pharming Group N.V. has announced plans to develop leniolisib for additional primary immunodeficiencies (PIDs) beyond activated phosphoinositide 3-kinase delta syndrome (APDS). The company plans to initiate a Phase 2 clinical trial in the second quarter of 2024, focusing on PIDs linked to immune dysregulation associated with PI3Kδ signaling. The trial aims to assess safety, tolerability, pharmacokinetics, and clinical efficacy in about 12 patients. This development is notable as it seeks to address the lack of approved therapies for these rare genetic disorders.
Read more →PHARPharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib
Pharming Group N.V. has dosed its first patient in a Phase III clinical trial aimed at evaluating a new pediatric formulation of leniolisib for children aged 1 to 6 years with activated phosphoinositide 3-kinase delta syndrome (APDS). The trial will assess the safety, tolerability, and efficacy in 15 young patients. This initiative reflects Pharming's commitment to expanding treatment options for pediatric patients suffering from this rare immunodeficiency disorder. Leniolisib is already approved for older patients and aims to provide significant benefits for younger patients, improving their overall participation in typical childhood activities.
Read more →PHAR▼ -10.8%on this news
Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approval
Pharming Group N.V. has announced updates regarding its Marketing Authorization Application (MAA) for leniolisib, a treatment for Activated Phosphoinositide 3-Kinase δ Syndrome (APDS). The European Medicines Agency (EMA) has issued a Day 180 Second List of Outstanding Issues, with a decision expected in the first quarter of 2024. In addition, Pharming intends to submit an MAA to the UK's MHRA through the International Recognition Procedure following the approval already granted by the US FDA. Leniolisib has shown clinical efficacy and is currently under regulatory review in multiple regions.
Read more →PHARPharming Group announces presentations at International Primary Immunodeficiencies Congress and the American College of Allergy, Asthma & Immunology Annual Scientific Meeting
Pharming Group N.V. announced that it will showcase 14 poster presentations at the International Primary Immunodeficiencies Congress and the American College of Allergy, Asthma & Immunology Annual Scientific Meeting in November 2023. The presentations primarily focus on leniolisib, an innovative treatment for activated phosphoinositide 3-kinase delta syndrome. Key findings will discuss the long-term efficacy and safety of leniolisib, along with its impacts on patient quality of life. This highlights Pharming's commitment to addressing rare and complex diseases in global healthcare settings.
Read more →PHARPharming Group to participate in November investor conferences
Pharming Group N.V. is set to participate in several investor conferences this November, including the Stifel 2023 Healthcare Conference and the Jefferies London Healthcare Conference. Key company executives, including the Chief Medical Officer and CEO, are scheduled to present and engage in discussions. This involvement indicates Pharming's efforts to strengthen investor relations and highlight its developments in biopharmaceuticals. Interested parties can schedule one-on-one meetings with the management team during these events.
Read more →PHAR▲ +5%on this news· ran to +15% by day 5shared move
Pharming Group reports third quarter 2023 financial results
Pharming Group reported a robust financial performance for Q3 2023, with revenues increasing by 23% to $66.7 million, primarily driven by strong sales of RUCONEST® and the successful commercial launch of Joenja®. The company highlighted a total revenue of $164.1 million for the first nine months of 2023, marking a 9% increase year-over-year. However, revenue growth for RUCONEST® is projected to remain modest, and the company continues to focus on enhancing patient access and diagnosis strategies. Pharming is also progressing on regulatory submissions for Joenja® in various countries.
Read more →PHARPharming Group to report third quarter 2023 financial results on October 26
Pharming Group N.V. has announced it will release its preliminary third quarter 2023 financial results on October 26, 2023. A conference call will be held at 13:30 CEST/07:30 EDT the same day, with advance registration required for participants. The company continues to support patients with rare diseases through its portfolio of protein replacement therapies and precision medicines, operating in over 30 global markets.
Read more →PHARPharming Group reports on results of the 2023 Extraordinary General Meeting of Shareholders
Pharming Group N.V. reported that all proposals from its 2023 Extraordinary General Meeting of Shareholders were adopted. Key highlights include the appointment of Dr. Richard Peters as the new Non-Executive Director, succeeding Paul Sekhri as Chair of the Board. The leadership transition marks a continuation of Pharming's strategic objectives focused on growth in the rare disease market. Shareholders also approved a proposal for an annual fee increase for the Board Chair, reinforcing confidence in the company's governance.
Read more →PHARPharming Group to participate in September investor conferences Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following...
Pharming Group N.V. will participate in several investor conferences in September 2023, including the Wells Fargo Healthcare Conference and the H.C. Wainwright 25th Annual Global Investment Conference. CEO Sijmen de Vries and VP Michael Levitan will represent the company, engaging in presentations and Q&A sessions. Live webcasts will be available for those unable to attend in person.
Read more →PHARPharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been enrolled in its...
Pharming Group N.V. has announced the enrollment of the first patient in its Phase III clinical trial of leniolisib for treating activated phosphoinositide 3-kinase delta syndrome (APDS) in Japan. This trial aims to assess the safety and efficacy of leniolisib in patients aged 12 and older. The results will be included in a future registration application to Japan's PMDA. The trial represents a significant step for patients with APDS, who currently lack approved therapies.
Read more →PHAR▼ -6.3%on this news
Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has nominated...
Pharming Group N.V. has nominated Dr. Richard Peters as the new Chairman of the Board. His appointment will be confirmed at an upcoming Extraordinary General Meeting of Shareholders. Dr. Peters brings over 30 years of experience in the healthcare industry, including leadership roles in rare diseases. He aims to help Pharming achieve its long-term goals.
Read more →PHAR▲ +6.3%on this newsshared move
Pharming Group to report second quarter and first half 2023 financial results on August 3 Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and...
Pharming Group N.V. will announce its preliminary second quarter and first half 2023 financial results on August 3, 2023. The company will also host a presentation for analysts and investors at 13:30 CEST. Pharming is dedicated to developing innovative therapies for patients with rare and life-threatening diseases.
Read more →PHARPharming Group announces ADSs admitted to trade on Nasdaq under the symbol PHAR U.S. SEC declares registration statements effective Each ADS represents 10 ordinary shares The Company s ordinary shares continue to trade o
Pharming Group announces ADSs admitted to trade on Nasdaq under U.S. SEC declares registration statements effective Each ADS represents 10 ordinary shares The Company s ordinary shares continue to trade on Euronext Amsterdam No new shares issued in connection with the Nasdaq
Read more →PHARPharming Reports On Preliminary Financial Results 2013
LEIDEN, Netherlands, March 6, 2014 (GLOBE NEWSWIRE) -- Revenues and other income decreased to 7.0 million (2012: 10.9 million) mainly as a result from lower license fees as 2012 included receipt of a 7.9 million milestone from our US partner Santarus for successful completion of
Read more →PHARPHARMING AND SALIX ANNOUNCE EXTENSION OF PDUFA ACTION DATE FOR RUCONEST(r)
LEIDEN, Netherlands and RALEIGH, N.C., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Pharming Group NV (NYSE Euronext:PHARM) and Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) today announced that the Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) Actio
Read more →PHARPHARMING AND SANTARUS ANNOUNCE NEW DATA FROM OPEN-LABEL REPEAT TREATMENT STUDY WITH RUCONEST (RECOMBINANT HUMAN C1 ESTERASE INHIBITOR)
LEIDEN, Netherlands and SAN DIEGO, Nov. 8, 2013 (GLOBE NEWSWIRE) -- Pharming Group NV (NYSE Euronext: PHARM) and Santarus, Inc. (NASDAQ: SNTS) announced that new data from an open-label extension of the pivotal Phase III clinical study with RUCONEST( ) (recombinant human C1 e
Read more →PHARPharming Reports On Financial Results For The First Nine Months Of 2013
LEIDEN, Netherlands, Nov. 7, 2013 (GLOBE NEWSWIRE) -- Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today published its financial report for the first nine months of 2013. FINANCIAL HIGHLIGHTS * Revenues and other income increased to
Read more →PHARPharming announces EU12.0 million private equity placement with institutional investors
LEIDEN, Netherlands, Oct. 9, 2013 (GLOBE NEWSWIRE) -- Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it has entered into a private equity placement of 12.0 million ( 11.5 million net proceeds after subtraction of tr
Read more →PHARPharming's Marketing Authorization Application for Rhucin -- RHC1INH -- Accepted for Review by EMEA
LEIDEN, Netherlands, Aug. 17, 2006 (PRIMEZONE) -- Biotech company Pharming Group N.V. ("Pharming") (Euronext:PHARM) (PHARM.AS) announced today that its Marketing Authorization Application (MAA) for recombinant human C1 inhibitor (rhC1INH or Rhucin(R)) for treatment of acute attac
Read more →PHARPharming Presents rhC1INH Update at International Meetings
LEIDEN, Netherlands, Nov. 17, 2005 (PRIMEZONE) -- Biotech company Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (PHARM.AS) announced today that the Company presented clinical results of recombinant human C1 inhibitor (rhC1INH) at several international meetin
Read more →PHARPharming Candidate for Amsterdam Midkap Index on Euronext
LEIDEN, Netherlands, Nov. 09, 2005 (PRIMEZONE) -- Biotech company Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (PHARM.AS) announced today that it has been selected by Euronext Indices B.V. (Euronext) as a candidate for inclusion in the Amsterdam Midkap inde
Read more →PHARPharming Announces Results for First Nine Months 2005
LEIDEN, Netherlands, Nov. 3, 2005 (PRIMEZONE) -- Highlights: upcoming product filings, licensing progress and pipeline expansion. Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (PHARM.AS) announced today its financial results for the third quarter of 2005 and
Read more →PHARPharming Appoints New Head of Finance and Administration
LEIDEN, Netherlands, Oct. 24, 2005 (PRIMEZONE) -- Biotech company Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (PHARM.AS) announced today that it has appointed Mr. Wim J. E. Burgemeestre as Head of Finance and Administration effective October 24, 2005. Mr.
Read more →PHARPharming Presents Human Lactoferrin Results at International Conference
LEIDEN, Netherlands, Oct. 19, 2005 (PRIMEZONE) -- Biotech company Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (PHARM.AS) announced today results from three studies which demonstrate that human lactoferrin produced by Pharming (rhLF) can be considered safe
Read more →PHARPharming Expands Clinical Development of Recombinant Human C1 Inhibitor for new Indications
LEIDEN, Netherlands, Sept. 29, 2005 (PRIMEZONE) -- Biotech companyPharming Group N.V. ("Pharming" or "the Company") (Euronext:PHARM) (PHARM.AS) announced today that it will commence clinical development of recombinant human C1 inhibitor (rhC1INH) for new indications beyond heredi
Read more →PHARPharming to Present at UBS Global Life Sciences Conference
LEIDEN, Netherlands, Sept. 20, 2005 (PRIMEZONE) -- Biotech company Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (PHARM.AS) announced today that the Company will present at the UBS Global Life Sciences Conference (September 26-29, 2005) in New York. Dr. Fra
Read more →PHARPharming's Recombinant Human Fibrinogen Selected for U.S. Army Project
LEIDEN, Netherlands, Aug. 31, 2005 (PRIMEZONE) -- Biotech company Pharming Group N.V. ("Pharming" or "the Company") (Euronext:PHARM) (PHARM.AS) announced today that its recombinant human fibrinogen (rhFIB) product has been selected for a US Army project. Pharming's rhFIB will be
Read more →PHARPharming Announces First Half 2005 Results
LEIDEN, Netherlands, Aug. 19, 2005 (PRIMEZONE) -- Biotech company Pharming Group N.V. ("Pharming" or "the Company") (Euronext:PHARM) (PHARM.AS) (Other OTC:PHGUF) announced today its results for the first half (H1) of 2005 and second quarter ended June 30, 2005. Key Developments
Read more →PHARPharming Receives Japanese Patent on Recombinant Human Lactoferrin
LEIDEN, Netherlands, Aug. 10, 2005 (PRIMEZONE) -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (PHAR.AS), a biotechnology company, announced today that it has been granted a patent on recombinant human lactoferrin (rhLF) from the Japanese Patent Office. Th
Read more →PHARPharming Announces Research Collaboration With NovaThera
LEIDEN, Netherlands, July 12, 2005 (PRIMEZONE) -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext:PHARM) (PHARM.AS) announced today a research collaboration with NovaThera Limited ("NovaThera"). NovaThera was founded to commercialize pioneering technologies emanating
Read more →PHARPharming to Receive Milestone Payment from Esteve
LEIDEN, Netherlands, July 4, 2005 (PRIMEZONE) -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext:PHARM) announced today that it will receive a milestone payment from Laboratorios del Dr. Esteve, S.A. ("Esteve"). The milestone payment relates to the clinical developmen
Read more →PHARPharming Announces Partnership With AgResearch For Human Lactoferrin
LEIDEN, Netherlands, June 30, 2005 (PRIMEZONE) -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext:PHARM) (PHAR.AS) announced today a partnership with AgResearch Limited ("AgResearch") on the production of recombinant human lactoferrin ("rhLF"). In addition, Pharming h
Read more →PHARPharming Announces Key Appointments To Strengthen Organization
LEIDEN, Netherlands, June 24, 2005 (PRIMEZONE) -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext:PHARM) announced key appointments to further strengthen its organization in preparation for upcoming filings on recombinant human C1 inhibitor, lactoferrin and to acceler
Read more →PHARPharming Announces First Quarter 2005 Results
LEIDEN, Netherlands, May 6, 2005 (PRIMEZONE) -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext:PHARM) (PHAR.AS) announced today its first quarter (Q1) results for the period ended March 31, 2005. The Company reported on its strong financial position and progress with
Read more →PHARPharming Presents Phase II / III Clinical Results With Recombinant Human C1 Inhibitor
LEIDEN, Netherlands, May 2, 2005 (PRIMEZONE) -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext:PHARM) (PHAR.AS) announced today clinical results from Phase II/III clinical studies with recombinant human C1 inhibitor ("rhC1INH") for the treatment of hereditary angioed
Read more →PHARPharming Receives Over 800,000 Shares from Trust Foundation
LEIDEN, Netherlands, April 29, 2005 (PRIMEZONE) -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext:PHARM) (PHAR.AS) announced today that the Company is the beneficiary of over 800,000 Pharming shares. These shares stem from Stichting Pharming Trust Beheer ("SPTB"), a
Read more →PHARPharming Announces Annual Shareholders Meeting
LEIDEN, Netherlands, April 22, 2005 (PRIMEZONE) -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext:PHARM) (PHAR.AS) announced that the Company's annual shareholders meeting (AGM) will be held on May 10, 2005. The Company will present a business update, its annual acco
Read more →PHARPharming to Present at UBS Northern Europe Conference
LEIDEN, Netherlands, April 11, 2005 (PRIMEZONE) -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext: PHARM) (PHAR.AS) announced today that the Company will present at the UBS Northern Europe Small and Mid Cap Conference (April 12-14, 2005) in London. Pharming will be
Read more →PHARPharming Included in Next 150 Index on Euronext
LEIDEN, The Netherlands, March 24, 2005 (PRIMEZONE) -- Pharming Group N.V. ("Pharming" or "the Company") (Euronext:PHARM) (PHAR.AS) (Other OTC:PHGUF) announced today that the Company has been included in the Next 150 Index on the stock exchange of Euronext N.V. (Euronext). The N
Read more →PHARPharming Initates Phase III Clinical Trial for C1 Inhibitor in Europe
LEIDEN, The Netherlands, April 28, 2004 (PRIMEZONE) -- Pharming Group N.V. (Euronext: PHARM; "Pharming" or "the Company") announced today that it has initiated the pivotal Phase III clinical trial for recombinant human C1 inhibitor ("rhC1INH") for Hereditary Angioedema (HAE) in E
Read more →Competitive Position
How PHAR ranks across every disease it competes inCompetitive Position is a premium feature
See how PHAR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial